Virtual reality platform on head mounted display: Enhance Virtual Reality platform on a Meta Quest head mounted display
Study summary
The goal of this randomized feasibility clinical trial is to identify participant recruitment and retention, acceptability, and adherence to virtual reality training in people undergoing hemodialysis. The main question it aims to answer is if virtual reality could be a feasible and acceptable intervention in this setting.
The investigators will compare participants on virtual reality training during the standard dialysis session with those treated with standard dialysis session alone to see if a cognitive training using immersive virtual reality in people on hemodialysis is feasible and acceptable.
Participants randomised in the intervention group will use virtual reality during the standard dialysis session for 30 minutes, three times a week for 12 weeks. The virtual reality intervention will consist of computerized cognitive training of 4 games. Each exercise delivered to the participant will specifically provide training in a specific cognitive category (memory, cognitive flexibility, processing, attention, and memory). Participants randomised in the control group will perform the standard hemodialysis session three times a week for 12 weeks, without using virtual reality.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Adult participants aged 18 years or older and less than or equal to 75 years of age
* Receiving haemodialysis treatment for kidney failure for at least 90 days (permanent reduction in kidney function below an estimated glomerular filtration rate of 15 mL/minute per 1.73 m2)
* Able to provide written and informed consent
* Able to use the immersive virtual reality headset and follow instructions with sufficient motor, visual and auditory function to interact with the intervention
* Able to speak and understand Italian language
Exclusion Criteria:
* Severe cognitive impairment or psychiatric diseases leading to inability to follow instructions and use the virtual reality headset
* Significant nystagmus and/or vertigo leading to inability to tolerate the virtual reality headset
* Insufficient motor function to use the virtual reality system
* Hearing or visual disability
* Advanced or uncompensated chronic diseases unrelated to kidney failure (e.g. advanced cancer, heart failure, lung diseases with poor oxygen saturation)
* Other neurological diseases (ictus, Alzheimer's or other forms of dementia)
* Persistent pain or itch or who using opioids that may interfere with the tests or any other condition that the clinician may judge as influencing the results
Primary outcome measure(s)
Accept the invitation to participate — 4, 12 weeks Proportion of screened patients who participate in one or more sessions of allocated virtual reality training.
Appropriateness of eligibility criteria — 12 weeks Recruitment rate during 12 weeks of recruitment phase.
Retention — 12 weeks Proportion of randomized participants who complete the intervention and complete follow-up at 12 weeks.
Acceptability — 12 weeks Proportion of randomized participants who complete \>80% of the treatments during 12 weeks follow-up.
Proportion of adverse events — 12 weeks Proportion of randomized participants who have adverse event reporting completed at 12 weeks.
Quality of life — 0, 4, 12, 24 weeks Proportion of randomized participants who complete the outcome measurements using the Kidney Disease Quality of Life Short Form 36 (KDQOL-36). The KDQOL-36 has five scales, including two generic health related quality of life scales from the SF-12 version 1 (12 items total) and three kidney-specific scales (24 items total). Each of the KDQOL-36 kidney-targeted scales are scored by transforming all items linearly to a 0-100 possible range and averaging the items in the scale. On the KDQOL-36, higher scores indicate better health realated quality of life.
Trial sites (2)
Facility
City
Region
Status
University of Bari
Bari
BA
Univerity Vanvitelli
Naples
Italy
More University of Campania Luigi Vanvitelli trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
